Introduction {#sec0001}
============

Smoking is one of the leading causes of premature death ([@bib0024]). The majority of adult smokers (80--90%) initiate smoking during adolescence ([@bib0034]) and genetic factors were found to explain 44% of the individual differences ([@bib0033]). Adolescence is thus associated with an increased risk of developing long-lasting dependencies to nicotine and other substances ([@bib0031]), rendering this developmental period critical for the investigation of genetic risk factors and the resulting neurobehavioral mechanisms implicated in tobacco smoking. However, our knowledge on how genes influence brain mechanisms in smoking is limited, and existing findings are often based on sample sizes not large enough to yield conclusive results ([@bib0022]). Moreover, the investigation of smoking in adolescents is often hampered by reporting biases resulting from self-report measures ([@bib0013]), thus requiring complementation by biologically-verified markers of nicotine use such as cotinine ([@bib0015]).

Smoking in adolescence, in particular smoking initiation, is influenced by behaviours such as risk taking and impulsiveness, which reflect dissociation between the development of the subcortical reward system and a comparatively delayed maturation of cortical inhibitory functions characteristic for this developmental period ([@bib0020]). In adult smokers this maturation is complete, together with the direct consequence of chronic tobacco exposure, resulting in a neurobehavioral context distinct from that in adolescents. This suggests that genetic factors and the biological processes mediating smoking behaviour may be different in adolescents and adults. For example in adults, it has previously shown that a gene-cluster containing the dopamine receptor 2 (*DRD2*), the ankyrin repeat and kinase domain containing 1 (*ANKK1*) and the tetratricopeptide repeat domain 12 (*TTC12*) genes, is associated with tobacco smoking ([@bib0005], [@bib0006]). Similar results were found in adolescents with associations stronger in adolescence than in mid-adulthood ([@bib0005]). While this observation supports the notion of shifting biological processes underlying tobacco smoking across the life span, the mechanisms by which variations in this gene-cluster exert their biological effect on smoking behaviour and smoking initiation in adolescents have not yet been elucidated.

*TTC12, ANKK1* and *DRD2* are located in close proximity on chromosome 11 in a region of high linkage disequilibrium (LD). In addition to nicotine, the gene-cluster has been implicated in alcohol and opiate addiction ([@bib0023], [@bib0035], [@bib0037]), suggesting that its influence on smoking may be exerted through a mechanism which is not substance-specific. *TTC12* encodes for the tetratricopeptide repeat domain 12 protein, which is implicated in dopaminergic transmission and neurodevelopment ([@bib0001]). *ANKK1* is hypothesized to encode a signalling protein which mediates the expression of *DRD2* ([@bib0010]). *DRD2* in turn has a central role in regulating the dopamine reward system that mediates the reinforcing effects of all known addictive substances including nicotine mainly through striatal dopaminergic transmission ([@bib0028]). While other dopamine-related genes have been associated to smoking behaviours ([@bib0009]), we were interested in further investigating the role of this genetic region in early smoking initiation ([@bib0021]) and in characterising the molecular and neurological mechanisms underlying this association.

Specifically, we aimed (i) to identify single nucleotide polymorphisms (SNPs) in the *TTC12-ANKK1-DRD2* gene-cluster, associated with self-reported cigarette smoking in adolescents through meta-analysis of smoking data from 14,084 youths and blood cotinine levels, an objective measure of nicotine exposure, in a subset of 2,540 youths, (ii) to functionally characterize relevant SNPs by measuring allele-specific gene expression in human post-mortem striatal brain tissue and (iii) to assess the genotype effect on reward sensitivity by analysing its relation with the blood-oxygen level-dependent (BOLD) response in the ventral striatum during reward anticipation, risk taking and tobacco smoking in a subset of adolescents from the IMAGEN sample ([Fig. 1](#fig0001){ref-type="fig"}).Fig. 1Study aims, statistical analysis strategy, and results.Fig 1

Experimental procedures {#sec0002}
=======================

Participants {#sec0003}
------------

We included 4512 adolescents from the Northern Finland Birth Cohort NFBC1966 ([@bib0026]), 4307 from NFBC1986 ([@bib0030]), 3674 from the Avon Longitudinal Study of Parents and Children (ALSPAC) ([@bib0007]), and 1591 (of which 1263 had data on functional Magnetic Resonance Imaging (fMRI) data and 1085 on risk taking) from IMAGEN ([@bib0027]). Demographic characteristics and phenotypic distribution of the samples are reported in [Table 1](#tbl0001){ref-type="table"}.Table 1Demographic characteristics and phenotypic distribution of the study samples.Table 1:NFBC1966NFBC1986ALSPACIMAGENWhole samplefMRI sampleRisk-taking sampleTotal (*N*)451243073674159112631085Male (in %)47.347.65149.648.948.9Age in years141615141414CountryFinlandFinlandU.KGermany, U.K., France, IrelandGermany, U.K., France, IrelandGermany, U.K., France, IrelandYear of assessment198020022006200820082008*Never-Tried* n1436153919351139914771 %31.8335.7352.6771.5972.4071.10*Ever-Tried* *n*307627681739452349314 %68.1764.2647.3328.4127.6028.90*Smokers* *n*757982891189146133 %16.7822.824.2511.8811.4012.30*Weekly-smokers* *n*3098443711007165 %6.8519.6010.106.295.606.00[^2]

Smoking-related phenotypes {#sec0004}
--------------------------

Lifetime smoking, measuring the number and occasions of cigarette smoking adapted for adolescents who have lesser degree of exposure to smoke than adults, was self-reported in each cohort (see Supplementary-Material for details in each cohort; [@bib0005]), and recoded into four categories: *Never-Tried* (never smoked), *Ever-Tried* (smoked at least once), *Smokers* (smoked more than once in the last 30 days), as previously used ([@bib0005]) and *Weekly-Smokers* (smoked at least once a week in the last month). We used *Never-Tried* as our reference group to contrast with *Ever-Tried,* and subsequently validated our results by further contrasting with adolescents who smoke occasionally (*Smokers*) and regularly (*Weekly-Smokers*).

Genetic data {#sec0005}
------------

We chose 33 SNPs based on data availability in the cohort that was genotyped first, i.e. NFBC1966. Not all of these 33 SNPs were available in each sample. (SNPs and LD structures for each sample can be found in Supplementary-Fig. 1, MAF of the separated cohorts can be found in Supplementary Table 1).

Cotinine level {#sec0006}
--------------

Plasma cotinine and genotypic data were available in *n* = 2540 ALSPAC participants (see Supplementary-Material).

Brain genotype and gene expression {#sec0007}
----------------------------------

We extracted gene expression levels of *TTC12, ANKK1* and *DRD2* in the striatum from the GEO series GSE25219 database ([@bib0014]). Probe clusters assessing expression across the entire transcript of *TTC12, ANKK1* and *DRD2* were extracted (Transcript Cluster IDs 3349453, 3349535 and 3391653, respectively). We independently replicated the association between *DRD2* expression levels (Transcript exon probe ID 3391671) and rs2236709 genotypes in 93 post-mortem cortical brain tissue samples of European ethnicity, SNPExpress ([@bib0008]).

Functional MRI {#sec0008}
--------------

Brain activation during reward anticipation was measured using a modified monetary incentive delay (MID) fMRI task ([@bib0017]) in a sample of 1263 individuals from the IMAGEN sample. Gender, recruitment site and handedness were included as covariates. Based on previous findings ([@bib0036]), we focused on the ventral striatum (bilateral) as regions of interest (ROIs) (family-wise-error (FWE)-corrected, *p *\< 0.05) as 9-mm spheres from the contrast 'anticipation of large reward \> anticipation of no reward' (± 15, 9, −9 in Montreal Neurological Institute (MNI) space) (see Supplementary-Materials for more details).

Risk taking {#sec0009}
-----------

We used the Cambridge Gambling Task (CGT) from the Cambridge Cognition Neuropsychological Test Automated Battery (CANTAB; Cambridge Cognition <http://www.cambridgecognition.com/>).

Statistical analyses {#sec0010}
--------------------

### Genetic-association analyses and meta-analysis {#sec0011}

Genetic data analysis used Plink v1.07 ([http://pngu.mgh.harvard.edu/∼purcell/plink/](http://pngu.mgh.harvard.edu/~purcell/plink/){#interref0002}) if not otherwise indicated. Single marker association analyses were conducted using logistic or linear regression (for binary or quantitative traits, respectively) (see also Supplementary-Materials). Each genotype was coded as the number of copies of the minor allele in all cohorts. Analyses controlled for gender, (all samples) age and site (IMAGEN).

Meta-analysis was performed using the meta-analysis procedure from Plink. Significant results after Bonferroni-correction were investigated further (see also [Table 2](#tbl0002){ref-type="table"}).Table 2Association between SNPs spanning the *TTC12-ANKK1-DRD2* gene-cluster and smoking for *Ever-Tried* vs *Never-Tried*.Table 2:BPGeneSNPLocationMAFRef allele/N*PORQI^2^*Other alleleSamplesIndividuals(FEM)(REM)(FEM)(REM)112685412*TTC12*rs4517559Flanking 5′UTR0.3736C/T4135530.0021.080.2723.84112691986*TTC12*rs2236709Intron0.2588G/A4140810.0005\*1.10.660112693407*TTC12*rs7927508Intron0.3667G/A397620.0091.080.1546.93112694133*TTC12*rs2156486Intron0.1814G/T4135550.0080.920.830112699378*TTC12*rs723077Coding, Met73Leu0.4894C/A397710.060.940.630112704356*TTC12*rs10502172Intron0.4596T/C4136750.0040.930.1641.71112705919*TTC12*rs2303380Intron splice site0.3819G/A397710.491.020.1841.76112716539*TTC12*rs2288159Intron0.1561T/G397680.131.060.630112721133*TTC12*rs4987094Intron0.1004A/G397770.121.070.670112735810*TTC12*rs2276070Intron0.1541T/C397740.131.060.650112739889*TTC12*rs719802Intron0.3953T/C397720.361.030.338.76112739985*TTC12*rs719804Intron0.249G/A397590.061.070.760112749387*TTC12*rs2282511Flanking 3′UTR0.3455A/C3117640.111.080.0957.82112754346*TTC12*rs754672Flanking 3′UTR0.4894T/C4135520.0020.920.480112761718*ANKK1*rs877138Flanking 5′UTR0.3431G/A397770.251.040.370112768580*ANKK1*rs4590907Intron0.1436G/T4135770.231.040.760112772031*ANKK1*rs7118900Coding, Ala239Thr0.1896A/G397670.240.950.880112775225*ANKK1*rs4938016Coding, Gly442Arg0.4452G/C3119660.0021.090.50112775370*ANKK1*rs2734849Coding, His490Arg0.4886G/A4135800.010.940.318.9112776038*ANKK1*rs1800497Coding, Glu713Lys, TaqIA0.2026A/G4135490.470.980.710112788669*DRD2*rs6277Coding, Pro219Pro0.12201A/G3119810.0040.920.570112801119*DRD2*rs1076563Intron0.4127C/A397730.070.950.780112803549*DRD2*rs2471857Intron0.1577T/C397720.380.960.70112815891*DRD2*rs7125415Intron0.09914T/C397750.091.080.430112818599*DRD2*rs4648318Intron0.2538C/T397680.021.080.530112824662*DRD2*rs4274224Intron0.4823G/A397710.481.020.420112829684*DRD2*rs4581480Intron0.09919C/T397680.421.040.2820.71112834984*DRD2*rs7131056Intron0.4205C/A397620.141.050.370112846601*DRD2*rs4938019Intron0.1447C/T4135880.291.040.410112852165*DRD2*rs12364283Flanking 5′UTR0.07563G/A397650.940.10.980112857971*DRD2*rs10891556Intergenic0.1758T/G397720.511.030.355.8112860946*DRD2*rs6589377Intergenic0.3776G/A4135810.661.010.3410.46112863421*DRD2*rs4482060Intergenic0.30032T/A3119550.391.030.480[^3]

### Association of genotype and BOLD responses in the ventral striatum, brain activation and risk taking in the IMAGEN cohort {#sec0012}

We carried forward the results of the confirmatory analysis to investigate associations with brain activation and behavioural phenotypes underlying reward processing. ANOVAs comparing extracted mean ventral striatum BOLD responses across genotypes for those SNPs showing associations to self-reported smoking and cotinine were carried out in SPSS version 20.0 (IBM Corp., Armonk, NY). We explored associations of the smoking risk variants within *TTC12-ANKK1-DRD2* gene-cluster with risk taking. We expected to find positive associations between genetic risk for smoking and risk taking and tested for this association one-tailed.

Results {#sec0013}
=======

A summary of the main findings is illustrated in [Fig. 1](#fig0001){ref-type="fig"}.

Meta-analysis exploring the association between TTC12-ANKKI-DRD2 and smoking {#sec0014}
----------------------------------------------------------------------------

Comparing adolescents who *Never-Tried* smoking with those who *Ever-Tried* across four cohorts*,* we identified a significant association with rs2236709 (Risk allele G; Odds ratio (OR) = 1.10, 95% confidence interval (CI): 1.04--1.16, *p *= 5.0 × 10^−4^) ([Fig. 2](#fig0002){ref-type="fig"} and [Table 2](#tbl0002){ref-type="table"}). The minor G-allele of rs2236709 was linked to increased risk for smoking amongst subgroups of regular smokers (*Smokers* vs. *Never-Tried*: OR = 1.13, 95% CI: 1.05--1.22, *p *= 0.001; *Weekly-Smokers* vs. *Never-Tried*: OR = 1.16, 95% CI: 1.06--1.27, *p *= 0.001) ([Fig. 2](#fig0002){ref-type="fig"}B; Supplementary-Material Tables 2 and 3).Fig. 2Association between 33 single nucleotide polymorphisms (SNPs) covering the chromosome 11q23 *TTC12-ANKK1-DRD2* gene-cluster and self-reported smoking behavior in adolescence. Results of the meta-analyses across the NFBC1966, NFBC1986, ALSPAC and IMAGEN cohorts are reported. *p*-values were meta-*p*-values computed under fixed effect models. Given the multiple testing correction for all SNPs a significance threshold of 0.0015 was used. The blue diamond indicates the most significantly associated SNP. This was rs2236709 with *p *= 5.0 × 10^−4^ for *Ever-Tried* vs. *Never-Tried*, rs2236709 with *p *= 0.001 for *Smokers* vs. *Never-Tried* and rs2236709 with *p *= 0.001 for *Weekly Smokers* vs. *Never-Tried*. For other SNPs, diamonds are colored in a white-to-red scale corresponding to *R*^2^ values from 0 to 1 with the most significant SNPs. The SNP position refers to National Center for Biotechnology Information build 35. Estimated recombination rates are from HapMap and gene annotations are from UCSC genome browser with build. (B) Forest plots for rs2236709 for the comparisons of the reference group (i.e. *Never-Tried*) with *Ever-Tried, Smokers* and *Weekly-Smokers*. Box areas are proportional to the weight of the individual study. The overall summary odds ratios (OR) computed with a fixed effect model are represented by a diamond whose width indicate the 95% confidence interval (CI). Results of the analyses were as follows: *Ever-Tried* vs. *Never-Tried* OR = 1.10, 95%CI 1.04--1.16, *p *= 0.5.0 × 10^−4^; *Smokers* vs. *Never-Tried* OR = 1.13, 95% CI 1.05--1.22, *p *= 0.001 and *Weekly-Smokers* vs. *Never-Tried* OR = 1.16, 95% CI 1.06--1.27, *p *= 0.001 on the left, middle and right forest plots, respectively. (C, left plot) Association between 33 SNPs and cotinine level in the ALSPAC cohort. Blue diamond indicates the most significantly associated SNP (rs2236709), as determined by linear regression analyses. Other diamonds are color-coded in a white-to-orange scale corresponding to increasing *R*^2^ values of the respective SNP with rs2236709. The SNP position refers to National Center for Biotechnology Information build 35. Estimated recombination rates are from HapMap and gene annotations are from UCSC genome browser with build 35 coordinates. (C, right plot) Mean cotinine level (SE) according to rs2236709 genotypes (linear regression analysis: β = 0.11, *p *= 0.5.0 × 10^−4^). Mean~AA ~= 6.35, SE = 0.72, *n* = 1489; Mean~AG ~= 7.94, SE = 1.18, *n* = 900; and Mean~GG ~= 19.62, SE = 4.86, *n* = 151; post-hoc comparisons: AA vs. AG, *p *= 0.843, *R*^2 ^= 0.0005, AA vs. GG, *p *= 3.67E-5, *R*^2 ^= 0.02 and AG vs. GG, *p *= 0.001, *R*^2 ^= 0.013.Fig 2

Association of cotinine level and self-reported smoking behavior {#sec0015}
----------------------------------------------------------------

Higher cotinine levels correlated with a higher number of self-reported cigarettes (Spearman\'s *ρ *= 0.33, *p *= 3.7 × 10^−53^), thus validating self-reported smoking. Mean cotinine levels in ng/ml (SD) for each category of smokers were: *Never-Tried *= 0.73 (2.73), *Ever-Tried *= 15.18 (46.51), *Smokers *= 28.13 (61.64) and *Weekly-Smokers *= 64.97 (82.51). One-way ANOVA revealed significant difference across lifetime smoking categories (F(3,3319) = 25.09, *p *= 4.80 × 10^−16^, R^2 ^= 0.022). Stratification of mean plasma cotinine levels according to rs2236709 genotypes indicated a significant positive association with the minor G-allele \[F(2,2537) = 9.64, *p *= 6.76 × 10^−5^, *R*^2 ^= 0.003) ([Fig. 2](#fig0002){ref-type="fig"}C, Supplementary Table 4), thus confirming the association of rs2236709 with self-reported smoking.

Rs2236709 influences on striatal *DRD2* expression {#sec0016}
--------------------------------------------------

Rs2236709 is located within *TTC12* and is in LD with the other genes in the locus, *ANKK1* and *DRD2* (see Supplementary-Material Fig. 1). To investigate which of these three genes contributed to the effects of rs2236709 on smoking, we analysed their expression in post-mortem human brain samples. [Fig. 3](#fig0003){ref-type="fig"}A shows expression of *TTC12, ANKK1* and *DRD2* in the striatum across the lifetime. It was indicated that *DRD2* mRNA levels in the striatum increased steadily during the foetal stages and reached a peak in adolescence, while *ANKK1* and *TTC12* expression levels were low overall. We performed association analyses to investigate the effects of rs2236709 on striatal *DRD2, TTC12* and *ANKK1* expression and included developmental stage as a covariate. The minor G-allele of rs2236709 was associated with increased expression of *DRD2* in the striatum (*r *= 0.39, *p *= 0.013, df = 37; [Fig. 3](#fig0003){ref-type="fig"}B). Neither expression of *TTC12* nor that of *ANKK1* was influenced by rs2236709 genotypes (*p *= 0.176 and *p *= 0.244, respectively). There was no association of gender (*p *= 0.627) or RNA integrity (*p *= 0.296) with *DRD2* gene expression.Fig. 3(A) Expression of *DRD2, TTC12* and *ANKK1* in the human striatum across the lifetime. The *x*-axis represents different stages of fetal and postnatal development, as indicated. PCW = post-conception weeks, M = months, Y = years. (B) Striatal expression of *DRD2* corrected for effects of developmental stage and stratified by rs2236709 genotypes. The dotted line visualizes the linear regression against the number of minor G-alleles (*n*~AA ~= 22, *n*~AG ~= 16 and, *n*~GG ~= 5).Fig 3

As there is, to our knowledge, no other dataset contains expression levels of *DRD2* in the striatum and rs2236709 genotype data, we independently replicated the association between *DRD2* expression levels and rs2236709 in cortical brain tissue samples of European ethnicity ([@bib0008]), and found the association to be significant (*p*~uncorrected ~= 0.003, *p*~corrected ~= 0.049, corrected for the number of *DRD2* probes).

Association of rs2236709 genotype and ventral striatum BOLD response during reward anticipation {#sec0017}
-----------------------------------------------------------------------------------------------

As our results suggest that altered dopaminergic transmission in reward-related brain areas (e.g., the ventral striatum) may underlie the association of rs2236709 with smoking, we further measured associations of this variant with BOLD response during reward anticipation in the ventral striatum of 1236 IMAGEN participants. Due to a skewed allele distribution of rs2236709 (*n*~AA ~= 706, *n*~AG ~= 467, *n*~GG ~= 90), we pooled heterozygotes and GG-homozygotes (G-carriers) and compared them to AA-homozygotes. Our results show a significantly higher BOLD response in the left ventral striatum of G-carriers vs. AA-homozygotes \[F(1,1261) = 5.803, *p~uncorrected ~*= 0.016, *p*~corrected ~= 0.032, *R*^2 ^= 0.005, Supplementary-Materials), indicating an association of the risk allele (G) with greater reward sensitivity and increased *DRD2* expression. No significant associations of rs2236709 genotypes with BOLD response in the right ventral striatum (*p *= 0.237) were observed.

Association between risk taking, rs2236709, and ventral striatum BOLD response during reward anticipation {#sec0018}
---------------------------------------------------------------------------------------------------------

As we expected a positive association between genetic risk for smoking and risk taking, this association was tested one-tailed. Risk taking positively associated with risk allele (G) of rs2236709 (*r *= 0.056, *p *= 0.033), and ventral striatal BOLD response (left: *r *= 0.033, *p *= 0.112; right: *r *= 0.049, *p *= 0.034). Risk taking also significantly associated with the number of occasions of lifetime cigarette smoking (*r *= 0.056, *p *= 0.034).

Discussion {#sec0019}
==========

The current study carried out a neurobehavioral characterization of the *TTC12*-*ANKK1*-*DRD2* gene-cluster and smoking in adolescence using four large datasets from different European countries. Our result demonstrated that this gene-locus exerts its effect on smoking behaviors such as smoking initiation and frequency already in the very early stages of nicotine abuse. To attain a mechanistic understanding of the associations of the minor G-allele of rs2236709 with both increased self-reported nicotine intake and higher cotinine levels in adolescents, we found that the genetic risk factor rs2236709 regulates DRD2 gene expression, and is also associated with activation of ventral striatum during reward anticipation and risk taking, a behaviour associated with drug initiation.

*DRD2* is a key molecular determinant of reward sensitivity ([@bib0028]), which reaches its peak expression in the striatum during adolescence. High *DRD2* expression increases sensitivity to rewarding stimuli, thus increases sensitivity to the effects of substances ([@bib0004]) as well as risk taking ([@bib0002]). This combination increases vulnerability for addictive behaviors ([@bib0019]). Thus, enhanced *DRD2* expression in adolescents is likely to be one component of risk for substance abuse and smoking in particular. Whereas *DRD2* receptor availability is reduced during the compulsive stages of substance addiction ([@bib0012]), early substance use has been linked to increased *DRD2* expression levels in the ventral striatum ([@bib0018]), suggesting a differential regulation of *DRD2* in adolescents experimenting with drugs compared to established nicotine dependence in adults.

Our results suggest that carriers of rs2236709 G-risk allele are at a particularly high risk of nicotine abuse, presumably due to an allele-specific increase in *DRD2* expression, in carriers of the G-risk allele found in human post-mortem brain tissue retrieved from the striatum. While our cohorts have different ancestry the LD structure of the rs2236709 locus is similar, suggesting that the findings in the post-mortem human brains can be extended to all our cohorts. Concurrently, increased ventro-striatal response during reward anticipation was observed in carriers of the G-risk allele in functional neuroimaging analyses of 14 year-old IMAGEN participants. Together these findings suggest an enhanced (ventro-)striatal dopaminergic activity underlying the observed association. Our cognitive findings using the IMAGEN sample are in keeping with this interpretation, namely that carriers of the risk allele showed higher risk taking behavior, which in turn was associated with increased ventral striatal activation and with increased nicotine use.

We did not detect significant association between smoking frequency and ventral striatal activity in this sample of 14 year-old adolescents in which 72% had never smoked. This might be explained by insufficient exposure to cigarettes due to young age and/or reduced availability of cigarettes compared to older cohorts, such as NFBC1966 where only 32% adolescents had never smoked at that age.

Rs2236709 is localized in the second intron of the *TTC12* gene locus and tags a haplotype that ranges from the promoter to the third exon of the *TTC12* gene. While it is correlated with *DRD2* expression in the striatum, it is not associated with the expression of *TTC12* itself. However, it is well known that even *Cis*-acting gene expression can be regulated by genetic variations that are not immediately adjacent to the gene they are regulating ([@bib0016]).

This study has some limitations: (i) different cohorts applied different measures to assess smoking behaviour, which limited us from obtaining a continuous measure consistent across studies, but instead combined information into distinct groups. (ii) Smoking habits have been subject to changing societal and legal attitudes over the last decades. Data acquisition among the different cohorts spreads over several decades, which was not accounted for. (iii) Cotinine can also account for second hand smoking, moreover the half-life of cotinine being 16--18 h is much shorter than some of the self-reported smoking behaviours that measure longer tobacco use ([@bib0011], [@bib0025], [@bib0032]). (iv) Genetic heterogeneity between studies should be noted as we pooled all samples of European ancestry due to limited data on adolescent smoking. Two cohorts (NFBC1966, NFBC1986) were of Finnish ancestry, and genetically distinct from the other two European cohorts (IMAGEN, ALSPAC), which might limit generalization of our findings. Notably, despite some differences of the minor allele frequency (MAF), the direction of the smoking-risk SNP effects is consistent across cohorts and I^2^ of rs2236709 indicated no heterogeneity across cohorts.

Our work proposes a neurobiological pathway to nicotine abuse in a developmental period characterized by both vulnerability to the effects of nicotine, and great therapeutic potential to prevent or overcome its abuse ([@bib0029]). Noting the recent success of interventions targeting behavioral risk profiles ([@bib0003]), our neurobehavioral characterization provided a basis for developing interventions targeting biological mechanisms underlying nicotine abuse.
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[^1]: Authors had equal contribution

[^2]: *Notes*: The total sample size *N* was decomposed into participants, who never tried smoking (*Never-Tried*) as contrasted to those who have tried smoking at least once (*Ever-Tried*); this comparison is mutually exclusive. Out of those *Ever-Tried* participants, smokers and weekly smokers were taken; percentages refer to the total sample size (*N*).

[^3]: *Notes***:** Association between SNPs spanning the *TTC12-ANKK1-DRD2* gene-cluster and self-reported smoking behaviour. *Ever-Tried* (*N* = 8722) are compared to *Never-Tried* (*N* = 6049) (binary logistic regression). Results from NFBC1966, ALSPAC, NFBC1986 and IMAGEN have been combined using meta-analysis. FEM = Fixed effect model, REM = Random effect model, *Q *= Cochrane\'s *Q* statistic, *I^2 ^*= heterogeneity index (0--100), *N* = number of study samples. Significant p values are in bold, of these those that remain significant after Bonferroni correction for multiple testing are indicated by an asterisk. Thick lines indicate boundary between Linkage Disequilibrium blocks.
